Sichuan Kelun-Biotech’s Sac-TMT Gains Breakthrough Therapy Designation for NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its core product, sacituzumab tirumotecan (sac-TMT), in combination with tagitanlimab, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations. This designation, the fifth for sac-TMT, highlights its potential clinical advantages over existing treatments and aims to expedite its development and marketing. The announcement underscores the company’s strong position in the biopharmaceutical industry and its commitment to addressing urgent medical needs in cancer treatment.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focused on developing innovative treatments for advanced solid tumors such as non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer. The company holds proprietary intellectual property rights for its core product, sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate (ADC).

Average Trading Volume: 768,700

Technical Sentiment Signal: Buy

Current Market Cap: HK$76.91B

For detailed information about 6990 stock, go to TipRanks’ Stock Analysis page.